Having graduated from Napier College of Commerce and Technology (now Napier University) in 1986, I first worked in Sir Patrick Forrest's Breast Cancer Unit at the old Royal Infirmary of Edinburgh. I joined Imperial Cancer Research Fund (ICRF) at the Western General Hospital (Edinburgh) in 1989 and continued my research into breast and ovarian cancer there until relatively recently (being supported by CRUK and then Breakthrough Breast Cancer for the last five years). I moved to the School of Medicine at the University of St Andrews in November 2012.

Academic Publications -

(51) Moore, KM, Cerqueira V, MacLeod KG, Mullen P, Hayward RL, Green S, Harrison DJ, Cameron DA. & Langdon SP. Collateral-resistance to estrogen and HER-activated growth is associated with modified AKT, ERα and cell-cycle signaling in a breast cancer model. Explor Target Antitumor Ther. 2022 Feb 28; 3: 97–116.

(50) Sarr A, Bre J, Um I, Chan TH, Mullen P, Harrison DJ and Reynolds P. Genome-Scale CRISPR/Cas9 Screen Determines Factors Modulating Sensitivity to ProTide NUC-1031 (Scientific Reports 2019; Vol 9: article 7643: pp1-13 (https://doi.org/10.1038/s41598-019-44089-3).

(49) Lubbock A, Stewart G, O'Mahony F, Laird A, Mullen P, O'Donnell M, Powles T, Harrison DJ and Overton I. Overcoming Intratumoural Heterogeneity for Reproducible Molecular Risk Stratification: A Case Study in Advanced Kidney Cancer. (BMC Medicine: In Press).

(48) Meehan J, Ward C, Turnbull A, Jarman E, Xintaropoulou C, Martinez-Perez C, Pearson M, Mullen P, Supuran C, Harrison DJ, Kunkler IH and Langdon SP. Inhibition of pH regulation as a therapeutic strategy in hypoxic human breast cancer cells (Oncotarget. 2017 Apr 17. doi: 10.18632/oncotarget.17143).

(47) Wilkie RP, Neal AR, Johnston CA, Voute N, Lancefield CS, Medda F, Makiyi E, Rose E, Ojo OS, Slawin AMZ, Lebl T, Mullen P, Harrison DJ, Ireland C and Westwood NJ. Regio-selective lodocyclisation applied to the total synthesis of dehaloperophoramidine. (Chem Commun. 2016 ;52(71): 10747-50. doi: 10.1039/c6cc05747k.).

(46) Bown JL, Shovman M, Robertson P, Boiko A, Goltsov G, Mullen P and Harrison DJ. A Signaling Visualization Toolkit to support rational design of combination therapies and biomarker discovery: SiViT. (Oncotarget. 2016 May 18. doi: 10.18632/oncotarget.8747).

(45) Martinez-Perez C, Ward C, Turnbull AK, Mullen P, Cook G, Meehan J, Jarman E, Thomson PI, Campbell CJ, McPhail D, Harrison DJ and Langdon SP. Antitumour activity of the novel flavonoid Oncamex in preclinical breast cancer models. (Br J Cancer. 2016 Apr 12; 114(8):905-16).

(44) Riches A, Powis S, Mullen P, Harrison D, Hacker C, Lucocq J, Bowness J, Chapman A, Cameron R, McLornan L and Leung S. Human urinary exosomes in bladder cancer patients: properties, concentrations and possible clinical application. (Bladder 2016; 3(1): 1-7; e19.).

(43) Huang R, Langdon SP, Mullen P, Um IH, Faratian D and Harrison DJ. The role of HDAC2 in chromatin remodelling and response to chemotherapy in ovarian cancer. (Oncotarget: 2016; 7(4): 4695-4711).

(42) Ward, C, Meehan J, Mullen P, Supuran C, Dixon JM, Thomas JS, Winum J-V, Jarman EJ, Renshaw L, Um IH, Kay C, Kunkler IH, Harrison DJ and Langdon SP. Evaluation of Carbonic Anhydrase IX as a Therapeutic Target for Inhibition of Breast Cancer Invasion and Metastasis Using a Series of in vitro Breast Cancer Models. (Oncotarget. 2015; 6(28): 24856-70).

(41) Stewart GD, Laird A, O’Mahony FC, Eory L, Lubbock ALR, Nanda J, O’Donnell M, Mackay A, Mullen P, McNeill SA, Riddick ACP, Aitchison M, Berney D, Rashid S, Martin S, Bex A, Overton IM, Harrison DJ and Powles T. Sunitinib treatment exacerbates intratumoral heterogeneity in metastatic renal cancer. (Clin Cancer Res. 2015 Sep 15; 21(18): 4212-23).

(40) Martinez‐Perez C, Ward C, Cook G, Mullen P, McPhail D, Harrison DJ and Langdon SP. Novel flavonoids as anticancer agents: mechanisms of action and promise for their potential application in breast cancer. (Biochemical Society Transactions 2014; 42(4): 1017-23).

(39) Stewart GD, O'Mahony F, Laird A, Rashid S, Martin S, Eory L, Lubbock A, Nanda J, O'Donnell M, MacKay A, Mullen P, McNeill A, Riddick A, Aitchison M, Berney D, Bex A, Overton I, Harrison DJ and Powles T. Carbonic anhydrase 9 expression increases with VEGF targeted therapy and is predictive of outcome in metastatic clear cell renal cancer (European Urology 2014; 66: 956-963).

(38) Caie PD, Schuur K, Oniscu A, Mullen P, Reynolds PA and Harrison DJ. Human tissue in systems medicine. (FEBS J 2013; 280(23): 5949-5956).

(37) Ward C, Langdon SP, Mullen P, Harris AL, Harrison DJ, Supurand CT and Kunkler IH. New Strategies for Targeting the Hypoxic Tumour Microenvironment in Breast Cancer. (Cancer Treatment Reviews 2013; 39(2): 171-179).

(36) O'Mahony FC, Nanda J, Laird A, Mullen P, Caldwell H, Overton IM, Eory L, O'Donnell M, Faratian D, Powles T, Harrison DJ and Stewart GD. The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers. (J. Vis. Exp. 2013; (71): e50221, doi:10.3791/50221).

(35) Winum J-Y, Carta F, Ward C, Mullen P, Harrison D, Langdon SP, Cecchi A, Scozzafava A, Kunkler I and Supuran, CT. Ureido-substituted sulfamates show potent carbonic anhydrase IX inhibitory and antiproliferative activities against breast cancer cell lines. (Bioorganic & Medicinal Chemistry Letters 2012; 22: 4681-4685).

(34) Welman A, Sproul D, Mullen P, Muir M, Kinnaird AR, Harrison DJ, Faratian D, Brunton VG and Frame MC. Diversity of matriptase expression level and function in breast cancer. (PLoS One 2012; 7(4):e34182).

(33) Lebedeva G, Sorokin A, Faratian D, Mullen P, Goltsov A, Langdon SP, Harrison D, and Goryanin I. Model-based global sensitivity analysis as applied to identification of anti-cancer drug targets and biomarkers of drug resistance. (Eur J Pharm Sci 2012; 46(4): 244-58).

(32) Goltsov A, Faratian D, Mullen P, Langdon SP, Harrison DJ and Brown J. Features of the reversible sensitivity-resistance transition in PI3K / PTEN / AKT signalling network after HER2 inhibition. (Cell Signal 2012; 24(2): pp493-504).

(31) Faratian D, Sims AH, Mullen P, Kay C, Um IH, Langdon SP and Harrison DJ. Sprouty 2 is an independent prognostic factor in breast cancer and may be useful in stratifying patients for trastuzumab therapy. (PLoS One 2011; 6(8); e23772, pp1-9).

(30) Faratian D, Zweemer AJM, Nagumo Y, Sims AH, Muir M, Dodds M, Mullen P, Um IH, Kay C, Hasmann M, Harrison DJ and Langdon SP. Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies. (Clin Cancer Res 2011; 17(13): 4450-4460).

(29) Faratian D, Um IH, Wilson DS, Mullen P, Langdon SP and Harrison DJ. Phosphoprotein pathway profiling of ovarian carcinoma for the identification of potential new targets for therapy. (Eur J Cancer 2011; 47: 1420-1431).

(28) Hochgräfe F, Zhang L, O’Toole S, Browne BC, Mark Pinese M, Cubas AP, Lehrbach GM, Croucher DR, Rickwood D, Boulghourjian A, ShearerR, Nair R, Swarbrick A, Faratian D, Mullen P, Harrison DJ, Biankin AV, Sutherland RL, Raftery MJ and Daly RJ. Tyrosine phosphorylation profiling reveals the signaling network characteristics of basal breast cancer cells. (Cancer Research 2010; 70(22): 9391-401). (27) Langdon SP, Faratian D, Nagumo Y, Mullen P, Hasmann M and Harrison DJ. Pertuzumab for the treatment of ovarian cancer. (Expert Opin Biol Ther 2010; 10(7): 1113-1120).

(26) Nagumo Y, Faratian D, Mullen P, Harrison DJ, Hasmann, M and Langdon SP. Modulation of HER3 is a marker of dynamic cell signalling in ovarian cancer: Implications for Pertuzumab sensitivity. (Mol Cancer Res 2009; 7(9): 1563-1571).

(25) Faratian D, Goltsov A, Lebedeva G, Sorokin A, Moodie S, Mullen P, Kay C, Um IH, Langdon SP, Goryanin I, and Harrison DJ. Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumab. (Cancer Research 2009; 69(16): 6713-6720).

(24) Morgan K, Stewart AJ, Miller N, Mullen P, Muir M, Dodds M, Medda F, Harrison DH, Langdon SP and Millar RP. Gonadotropin-Releasing Hormone receptor levels and cell context affect tumor cell responses to agonist in vitro and in vivo. Cancer Research 2008; 68(15): 6331-6340.

(23) Langdon SP, Mullen P, Faratian D, Harrison DH, Cameron DA and Hasmann M. Pertuzumab. Drugs of the Future 2008; 33(2): 123-130.

(22) Mullen P, Cameron DC, Hasmann M, Smyth JF and Langdon SP. Sensitivity to Pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signalling. Molecular Cancer Therapeutics 2007; 6(1): 93-100.

(21) McPhillips F, Mullen P, MacLeod K, Monia BP, Smyth JF and Langdon SP. Raf-1 is the predominant Raf isoform that mediates growth factor-stimulated growth in ovarian cancer cells. Carcinogenesis 2006; 27(4): 729-739.

(20) Mullen P, McPhillips F, Monia BP, Smyth JF and Langdon SP. Comparison of strategies targeting Raf-1 mRNA in ovarian cancer. Int J Cancer 2006; 118(6): 1565-1571.

(19) MacLeod K , Mullen P, Sewell J, Rabiasz, GJ, Lawrie SL, Miller EP, Smyth JF and Langdon SP. Altered ErbB receptor signalling and gene expression in cisplatin-resistant ovarian cancer. Cancer Res 2005; 65(15): 6789-6800.

(18) Mullen P, McPhillips F, MacLeod K, Monia BP, Smyth JF and Langdon SP. Antisense oligonucleotide targeting of Raf1: Importance of mRNA levels in determining growth response in ovarian cancer. Clin Cancer Res 2004; 10 (6): 2100-2108.

(17) McPhillips F, Mullen P, Monia BP, Ritchie AA, Dorr FA, Smyth JF and Langdon SP. Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer. Br J Cancer 2001; 85: 1753-1758.

(16) Wilson KE, Bartlett JMS, Miller EP, Smyth JF, Mullen P, Miller WR and Langdon SP. Regulation and function of the extracellular matrix protein tenascin-C in ovarian cancer cell lines. Br J Cancer 1999; 80: 685-692.

(15) Miller WR, Mullen P, Telford J and Dixon JM. Clinical importance of intratumoral aromatase. Breast Cancer Res Treat. 1998; 49 Suppl 1:S27-32; discussion S33-7.

(14) Miller WR, Mullen P, Sourdaine P, Watson C, Dixon JM & Telford J. Regulation of aromatase activity within the breast. J Steroid Biochem Mol Biol 1997; 61(3-6): 193-202.

(13) Mullen P, Warner J, Langdon SP, Mackay J, Fitzpatrick DR, Brock D and Miller WR. BRCA1 5382insC mutation in sporadic and familial breast and ovarian carcinoma in Scotland. Br J Cancer 1997; 75(9): 1377-1380.

(12) Sourdaine P, Mullen P, White R, Telford J, Parker MG & Miller WR. Aromatase activity and CYP19 gene expression in breast cancers. J Steroid Biochem Mol Biol 1996; 59(2): 191-198.

(11) Mullen P, Ritchie A, Langdon SP & Miller WR (1996). Effect of matrigel on the tumourigenicity of human breast and ovarian carcinoma cell lines. Int J Cancer; 67: 816-820.

(10) Miller WR, Hawkins RA, Mullen P, Sourdaine P & Telford J. Aromatase inhibition: determinants of response and resistance. Endocrine-Related Cancer 1995; 2(1): 73-85.

(9) Miller WR & Mullen P. Factors influencing aromatase activity in the breast. J Steroid Biochem Molec Biol 1993; 44: 597-604.

(8) Mullen P, Bramley TA, Menzies G & Miller WR. Failure to detect Gonadotrophin-Releasing Hormone (GnRH) receptors in human benign and malignant breast tissue and in MCF-7 and MDA-MB-231 cancer cells. Eur J Cancer 1993; 29A (2): 248-252.

(7) Scott WN, Mullen P, and Miller WR. Factors influencing the response of MCF-7 cells to an agonist of luteinising hormone - releasing hormone. Eur J Cancer 1991; 27: 1458-1461.

(6) Mullen P, Scott WN & Miiller WR. Growth inhibition observed following administration of an LHRH agonist to a clonal variant of the MCF-7 breast cancer cell line is accompanied by an accumulation of cells in the G0/G1 phase of the cell cycle. Br J Cancer 1991; 63: 930-932.

(5) Langdon SP, Rabiasz GJ, Anderson L, Ritchie AA, Fergusson RJ, Hay FG, Miller EP, Mullen P, Plumb J, Miller WR & Smyth JF. Characterisation and properties of a small cell lung cancer cell line and xenograft WX322 with marked sensitivity to alpha-interferon. Br J Cancer 1991; 63: 909-915.

(4) Mullen P & Miller WR. DNA flow cytometry of breast cancer fine needle aspirates. Br J Cancer 1990; 61: 343-344.

(3) Mullen P & Miller WR. Response to the letter by Remvikos. Br J Cancer 1990; 61(2): 343.

(2) Mullen P & Miller WR. Variations associated with the DNA analysis of multiple fine needle aspirates obtained from breast cancer patients. Br J Cancer 1989; 59: 688-691.

(1) Levack PA, Mullen P, Anderson TJ, Miller WR & Forrest APM. DNA analysis of breast tumour fine needle aspirates using flow cytometry. Br J Cancer 1987; 56: 643-646.